Otsuka Of Japan Joins Other MNCs And Considers R&D Investment Deal With Korean Ministry
This article was originally published in PharmAsia News
Japan's Otsuka Pharmaceutical is considering signing a memorandum of understating regarding a research and development investment deal with the Korean Ministry of Health, Welfare and Family Affairs, the Korean agency disclosed May 29. Currently, Novartis Korea is in the process of signing a MOU in investing $100 million in R&D with the ministry, and Korean subsidiaries of AstraZeneca and Pfizer have signed the MOUs. Besides Ostuka, Sanofi-Aventis is also considering a similar investment. Korea requires a minimum of $100 million in such R&D investment deals. (Click here for more - Japanese language
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.